{"id":8134,"date":"2025-10-31T15:48:59","date_gmt":"2025-10-31T14:48:59","guid":{"rendered":"https:\/\/www.substipharm.com\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/"},"modified":"2025-10-31T16:13:18","modified_gmt":"2025-10-31T15:13:18","slug":"paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de","status":"publish","type":"news","link":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/","title":{"rendered":"Paris, 31 october 2025 &#8211; Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi."},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"8134\" class=\"elementor elementor-8134 elementor-8116\" data-elementor-post-type=\"news\">\n\t\t\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-top-section elementor-element elementor-element-4a6427b8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-eae-slider=\"1207\" data-id=\"4a6427b8\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1c5a88a9\" data-eae-slider=\"5353\" data-id=\"1c5a88a9\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-639b7294 elementor-widget elementor-widget-text-editor\" data-id=\"639b7294\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\n<p>Paris, 31 october 2025 \u2013 Substipharm annonce l\u2019acquisition de deux marques pharmaceutiques bien connues\u202f: Asp\u00e9gic\u00ae, acquise aupr\u00e8s d\u2019Opella, et Kard\u00e9gic\u00ae \/ Cardirene\u00ae, acquises aupr\u00e8s de Sanofi. Ces marques sont reconnues et utilis\u00e9es depuis des d\u00e9cennies par les professionnels de sant\u00e9 et les patients dans les domaines du soulagement de la douleur, de l\u2019inflammation, de la fi\u00e8vre et de la pr\u00e9vention cardiovasculaire. <\/p>\n\n\n\n<p><strong>Une op\u00e9ration strat\u00e9gique qui conjugue h\u00e9ritage pharmaceutique et continuit\u00e9 th\u00e9rapeutique.<\/strong><\/p>\n\n\n\n<p>Asp\u00e9gic\u00ae est disponible en France , au Benelux, et en Suisse en bo\u00eetes in packs de 100 mg, 500 mg, and 1000 mg. La pr\u00e9sentation en 250mg est \u00e9galement disponible en France. <\/p>\n\n\n\n<p>Kard\u00e9gic\u00ae \/ Cardirene\u00ae est disponible en bo\u00eetes de 75 mg, 160 mg, and 300 mg en France, Italie, et Maroc; Cardirene\u00ae 100 mg est \u00e9galement disponible en Italie.<\/p>\n\n\n\n<p>Asp\u00e9gic\u00ae est indiqu\u00e9 dans le traitement de la douleur, de la fi\u00e8vre et de l\u2019inflammation (analg\u00e9sique, antipyr\u00e9tique, anti-inflammatoire).<\/p>\n\n\n\n<p>Kard\u00e9gic\u00ae \/ Cardirene\u00ae est indiqu\u00e9 dans la pr\u00e9vention des \u00e9v\u00e9nements cardiovasculaires (traitement antiplaquettaire visant \u00e0 r\u00e9duire le risque de formation de caillots sanguins, d\u2019infarctus du myocarde et d\u2019accidents vasculaires c\u00e9r\u00e9braux).<\/p>\n\n\n\n<p>D\u00e9claration de L\u00e9opold Berthier, Pr\u00e9sident de Substipharm :<\/p>\n\n\n\n<p><em>Asp\u00e9gic et Kard\u00e9gic \/ Cardirene sont des noms familiers pour des millions de patients et de professionnels de sant\u00e9. Nous sommes fiers d\u2019en assurer la continuit\u00e9 au sein de Substipharm et de renforcer notre engagement \u00e0 fournir des m\u00e9dicaments de confiance aux patients.<\/em><\/p>\n\n\n\n<p><strong>\u00c0 propos de Substipharm<\/strong><\/p>\n\n\n\n<p>Substipharm est une entreprise biopharmaceutique ind\u00e9pendante fond\u00e9e il y a 30 ans \u00e0 Paris, sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de m\u00e9dicaments g\u00e9n\u00e9riques, de sp\u00e9cialit\u00e9s de marque et de vaccins. Pr\u00e9sente dans plus de cent pays, Substipharm s\u2019engage \u00e0 rendre les soins accessibles partout dans le monde. <\/p>\n\n\n\n<p>Contact Presse:<\/p>\n\n\n\n<p>Rapha\u00eblle Tisserand-Qu\u00e9r\u00e9<\/p>\n\n\n\n<p>Email: rtisserand@substipharm.com<\/p>\n\n\n\n<p>site Web: www.substipharm.com<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"has_eae_slider elementor-section elementor-top-section elementor-element elementor-element-60a585e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-eae-slider=\"1697\" data-id=\"60a585e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"has_eae_slider elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b7e6940\" data-eae-slider=\"76906\" data-id=\"b7e6940\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6996230 elementor-widget elementor-widget-image\" data-id=\"6996230\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"450\" src=\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2-1024x576.png\" class=\"attachment-large size-large wp-image-8127\" alt=\"\" srcset=\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2-1024x576.png 1024w, https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2-300x169.png 300w, https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2-768x432.png 768w, https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png 1280w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":8127,"template":"","class_list":["post-8134","news","type-news","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Paris, 31 october 2025 - Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi. - Substipharm<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Paris, 31 october 2025 - Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi. - Substipharm\" \/>\n<meta property=\"og:description\" content=\"Paris, 31 october 2025 \u2013 Substipharm annonce l\u2019acquisition de deux marques pharmaceutiques bien connues\u202f: Asp\u00e9gic\u00ae, acquise aupr\u00e8s d\u2019Opella, et Kard\u00e9gic\u00ae \/ Cardirene\u00ae, acquises aupr\u00e8s de Sanofi. Ces marques sont reconnues et utilis\u00e9es depuis des d\u00e9cennies par les professionnels de sant\u00e9 et les patients dans les domaines du soulagement de la douleur, de l\u2019inflammation, de la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/\" \/>\n<meta property=\"og:site_name\" content=\"Substipharm\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T15:13:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/\",\"url\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/\",\"name\":\"Paris, 31 october 2025 - Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi. - Substipharm\",\"isPartOf\":{\"@id\":\"https:\/\/www.substipharm.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png\",\"datePublished\":\"2025-10-31T14:48:59+00:00\",\"dateModified\":\"2025-10-31T15:13:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#primaryimage\",\"url\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png\",\"contentUrl\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.substipharm.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.substipharm.com\/fr\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Paris, 31 october 2025 &#8211; Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.substipharm.com\/fr\/#website\",\"url\":\"https:\/\/www.substipharm.com\/fr\/\",\"name\":\"Substipharm\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.substipharm.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.substipharm.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.substipharm.com\/fr\/#organization\",\"name\":\"Substipharm\",\"url\":\"https:\/\/www.substipharm.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.substipharm.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png\",\"contentUrl\":\"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png\",\"width\":1446,\"height\":219,\"caption\":\"Substipharm\"},\"image\":{\"@id\":\"https:\/\/www.substipharm.com\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Paris, 31 october 2025 - Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi. - Substipharm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/","og_locale":"fr_FR","og_type":"article","og_title":"Paris, 31 october 2025 - Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi. - Substipharm","og_description":"Paris, 31 october 2025 \u2013 Substipharm annonce l\u2019acquisition de deux marques pharmaceutiques bien connues\u202f: Asp\u00e9gic\u00ae, acquise aupr\u00e8s d\u2019Opella, et Kard\u00e9gic\u00ae \/ Cardirene\u00ae, acquises aupr\u00e8s de Sanofi. Ces marques sont reconnues et utilis\u00e9es depuis des d\u00e9cennies par les professionnels de sant\u00e9 et les patients dans les domaines du soulagement de la douleur, de l\u2019inflammation, de la [&hellip;]","og_url":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/","og_site_name":"Substipharm","article_modified_time":"2025-10-31T15:13:18+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/","url":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/","name":"Paris, 31 october 2025 - Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi. - Substipharm","isPartOf":{"@id":"https:\/\/www.substipharm.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#primaryimage"},"image":{"@id":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#primaryimage"},"thumbnailUrl":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png","datePublished":"2025-10-31T14:48:59+00:00","dateModified":"2025-10-31T15:13:18+00:00","breadcrumb":{"@id":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#primaryimage","url":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png","contentUrl":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2025\/10\/logo-aspegic-kardegic-2.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.substipharm.com\/fr\/news\/paris-31-october-2025-substipharm-renforce-son-portefeuille-avec-lacquisition-des-marques-emblematiques-aspegic-aupres-dopella-et-kardegic-cardirene-aupres-de\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.substipharm.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.substipharm.com\/fr\/news\/"},{"@type":"ListItem","position":3,"name":"Paris, 31 october 2025 &#8211; Substipharm renforce son portefeuille avec l\u2019acquisition des marques embl\u00e9matiques Asp\u00e9gic\u00ae aupr\u00e8s d\u2019Opella et Kard\u00e9gic\u00ae \/ Cardirene\u00ae aupr\u00e8s de Sanofi."}]},{"@type":"WebSite","@id":"https:\/\/www.substipharm.com\/fr\/#website","url":"https:\/\/www.substipharm.com\/fr\/","name":"Substipharm","description":"","publisher":{"@id":"https:\/\/www.substipharm.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.substipharm.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.substipharm.com\/fr\/#organization","name":"Substipharm","url":"https:\/\/www.substipharm.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.substipharm.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png","contentUrl":"https:\/\/www.substipharm.com\/wp-content\/uploads\/2021\/08\/fichier-1@2x.png","width":1446,"height":219,"caption":"Substipharm"},"image":{"@id":"https:\/\/www.substipharm.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/news\/8134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/types\/news"}],"version-history":[{"count":2,"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/news\/8134\/revisions"}],"predecessor-version":[{"id":8145,"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/news\/8134\/revisions\/8145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/media\/8127"}],"wp:attachment":[{"href":"https:\/\/www.substipharm.com\/fr\/wp-json\/wp\/v2\/media?parent=8134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}